Karyopharm Therapeutics, Inc.

Karyopharm Therapeutics, Inc. is considered overvalued and risky due to negative valuation metrics and poor stock performance, with a year-to-date return of -43.52% and a five-year decline of -97.66%, contrasting sharply with the S&P 500's gains.

As of March 15, 2018, Karyopharm Therapeutics, Inc. is considered overvalued and classified as "risky," with poor financial metrics and a year-to-date return of -57.32%, significantly underperforming compared to its peers and the S&P 500.

As of June 2, 2025, the trend is mildly bearish due to daily moving averages showing bearish momentum, despite some mildly bullish signals from the weekly MACD and KST, while monthly indicators like Bollinger Bands and OBV remain bearish.

As of March 2022, Karyopharm Therapeutics, Inc.'s management team includes Dr. Michael Kauffman (Co-Founder, CEO, Director), Mr. Barry Greene (Lead Independent Director), Dr. Mansoor Mirza (Director, Clinical Advisor), Ms. Christy Oliger (Director), Mr. Chen Schor (Director), and Mr. Garen Bohlin (Independent Director).

Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company that develops drugs targeting nuclear export for cancer treatment. As of March 2025, it reported net sales of $30 million and a net loss of $23 million, with a market cap of $37.71 million.

As of Jun 18, Karyopharm Therapeutics, Inc. has a market capitalization of 37.71 million and reported net sales of 142.13 million with a net profit of -62.52 million over the latest four quarters.